281 related articles for article (PubMed ID: 17188882)
1. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.
Maetzler W; Berg D; Schalamberidze N; Melms A; Schott K; Mueller JC; Liaw L; Gasser T; Nitsch C
Neurobiol Dis; 2007 Mar; 25(3):473-82. PubMed ID: 17188882
[TBL] [Abstract][Full Text] [Related]
2. Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease.
Yasuda T; Fukuda-Tani M; Nihira T; Wada K; Hattori N; Mizuno Y; Mochizuki H
Exp Neurol; 2007 Aug; 206(2):308-17. PubMed ID: 17604022
[TBL] [Abstract][Full Text] [Related]
3. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
4. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
[TBL] [Abstract][Full Text] [Related]
5. Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease.
Duan W; Zhang Z; Gash DM; Mattson MP
Ann Neurol; 1999 Oct; 46(4):587-97. PubMed ID: 10514095
[TBL] [Abstract][Full Text] [Related]
6. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.
Dong Z; Wolfer DP; Lipp HP; Büeler H
Mol Ther; 2005 Jan; 11(1):80-8. PubMed ID: 15585408
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease.
Iczkiewicz J; Jackson MJ; Smith LA; Rose S; Jenner P
Brain Res; 2006 Nov; 1118(1):239-50. PubMed ID: 16962083
[TBL] [Abstract][Full Text] [Related]
8. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
9. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
Teng X; Sakai T; Liu L; Sakai R; Kaji R; Fukui K
J Neurochem; 2006 May; 97(4):1126-35. PubMed ID: 16686692
[TBL] [Abstract][Full Text] [Related]
11. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
12. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
[TBL] [Abstract][Full Text] [Related]
13. A chemical neurotoxin, MPTP induces Parkinson's disease like phenotype, movement disorders and persistent loss of dopamine neurons in medaka fish.
Matsui H; Taniguchi Y; Inoue H; Uemura K; Takeda S; Takahashi R
Neurosci Res; 2009 Nov; 65(3):263-71. PubMed ID: 19665499
[TBL] [Abstract][Full Text] [Related]
14. Iron transport in Parkinson's disease.
Hirsch EC
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
[TBL] [Abstract][Full Text] [Related]
15. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
[TBL] [Abstract][Full Text] [Related]
16. Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology.
Conn KJ; Gao W; McKee A; Lan MS; Ullman MD; Eisenhauer PB; Fine RE; Wells JM
Brain Res; 2004 Oct; 1022(1-2):164-72. PubMed ID: 15353226
[TBL] [Abstract][Full Text] [Related]
17. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
18. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.
Greffard S; Verny M; Bonnet AM; Seilhean D; Hauw JJ; Duyckaerts C
Neurobiol Aging; 2010 Jan; 31(1):99-103. PubMed ID: 18457903
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss.
Iczkiewicz J; Rose S; Jenner P
Exp Neurol; 2007 Sep; 207(1):95-106. PubMed ID: 17643430
[TBL] [Abstract][Full Text] [Related]
20. Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment.
Korecka JA; Eggers R; Swaab DF; Bossers K; Verhaagen J
Restor Neurol Neurosci; 2013; 31(2):155-67. PubMed ID: 23271419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
